论文部分内容阅读
在过去10年间,大量的研究证实:急性粒细胞白血病(AML)的免疫学标志与预后有关,其中较公认的是CD_3 4~- AML预后较差,而CD_(15)~- AML预后较好,而对其它免疫学标志与预后的关系意见尚不统一。 作者对法国25个研究中心的341例成人AML的免疫学标志与预后的关系进行了研究分析。全部病例均符合FAB标准(M_0～M_7),年龄15～65岁,均无骨髓增生异常综合征(MDS)病史亦未接受过化疗放疗。341例AML均接受常规的DA方案诱导
In the past 10 years, a large number of studies have confirmed that the immunological markers of acute myeloid leukemia (AML) are related to prognosis. It is generally accepted that the prognosis of CD_3 4~-AML is poor, while the prognosis of CD_(15)~-AML is better. However, opinions on the relationship between other immunological markers and prognosis are not yet uniform. The authors studied the relationship between the immunological markers and prognosis of 341 adult AML in 25 research centers in France. All cases met the FAB standard (M_0 ~ M_7), aged 15-65 years old, had no history of myelodysplastic syndrome (MDS) or chemotherapy radiotherapy. 341 AML patients received routine DA induction